Printer Friendly

Amarantus BioScience appoints new member to strategic advisory board.

M2 PHARMA-March 7, 2016-Amarantus BioScience appoints new member to strategic advisory board

(C)2016 M2 COMMUNICATIONS

Amarantus BioScience Holdings Inc (OTCQB: AMBS), a biotechnology company focused on developing products for Regenerative Medicine, Neurology and Orphan Diseases, has appointed Brian E Harvey, MD PhD to its strategic advisory board, it was reported on Friday.

The new member of strategic advisory board will assist the firm's management team in developing and executing its strategy to accelerate FDA regulatory approval for its orphan drug range of products.

Dr Harvey recently served as vice president of US Regulatory Strategy at Pfizer. Prior to his time at Pfizer, Dr Harvey served as vice president of Regulatory Policy at Sanofi, where he was the Liaison with US Food and Drug Administration (FDA), served on the International Biologics and Biotechnology Taskforce and Biologics Key Issues Team and was on the Biotechnology Industry Organization (BIO) Regulatory Affairs Committee (RAC). He was the Signatory authority for Sanofi written comments to the FDA docket and was a member of the Sanofi Policy Development Committee.

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2016 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2016 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Pharma
Date:Mar 7, 2016
Words:185
Previous Article:Astellas names new senior vice president and head of Marketing Strategy.
Next Article:First Patients Enrolled in New Study to Expand Indication for NeoTract's UroLift System.
Topics:

Terms of use | Privacy policy | Copyright © 2020 Farlex, Inc. | Feedback | For webmasters